

Resource Summary Report

Generated by [NIF](#) on Sep 8, 2026

Hep-G2/C3A

RRID:CVCL_1098

Type: Cell Line

Proper Citation

RRID:CVCL_1098

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1098

Proper Citation: RRID:CVCL_1098

Description: Cell line Hep-G2/C3A is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Hepatoblastoma

Defining Citation: [PMID:12068308](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:29468137](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Virology: Susceptible to infection by Zika virus (ZIKV) (PubMed=29468137)., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Hep-G2/C3A

Synonyms: HepG2/C3A, Hep G2/C3A, C3A

Cross References: BTO:BTO_0003586, CLO:CLO_0002119, EFO:EFO_0002121, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, ATCC:CRL-3581, ATCC:CRL-10741, BCRC:60177, BCRJ:0291, BioSample:SAMN03473207, BioSample:SAMN10987645, cancercellines:CVCL_1098, Cell_Model_Passport:SIDM01237, ChEMBL-Cells:ChEMBL3308377, ChEMBL-Targets:ChEMBL1075402, CLS:305891,

Cosmic:724820, Cosmic:910850, Cosmic:1995354, Cosmic-CLP:910850, DepMap:ACH-001021, EGA:EGAS00001000610, EGA:EGAS00001000978, FCS-free:10-2-11-3-4-4, GDSC:910850, GEO:GSM886899, GEO:GSM887964, GEO:GSM1669638, IARC_TP53:21205, IARC_TP53:27688, IGRhCellID:C3A, LINCS_LDP:LCL-1927, PharmacDB:C3A_156_2019, PRIDE:PXD030304, Progenetix:CVCL_1098, PubChem_Cell_line:CVCL_1098, Ubigene:YC-C093, Wikidata:Q54882789

ID: CVCL_1098

Hierarchy: cvcl_0027

Record Creation Time: 20220427T220334+0000

Record Last Update: 20260905T180248+0000

Ratings and Alerts

No rating or validation information has been found for Hep-G2/C3A.

No alerts have been found for Hep-G2/C3A.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 125 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Zheleznyak A, et al. (2026) Epithelial-Mesenchymal Transition and Stress Adaptations Underlie Yttrium-90 Resistance in Liver Cancer Cell Lines. Cancer research communications, 6(1), 178.

Ahonen MH, et al. (2026) Pregnane X Receptor Regulates Human Endocrine System by Inducing Sex Hormone-Binding Globulin Expression. Basic & clinical pharmacology & toxicology, 138(4), e70218.

Meng WY, et al. (2026) SMD2 reads pseudouridines to regulate mRNA splicing and promote tumorigenesis. Molecular cell.

Wang M, et al. (2026) Biomaterial-minimalistic photoactivated bioprinting of cell-dense tissues. Cell, 189(1), 106.

Jordan P, et al. (2026) The hepatitis E virus capsid protein forms amyloid-like fibrils that sequester TANK-binding kinase 1 to dampen antiviral responses. Cell reports, 45(6), 117513.

- Turnham RE, et al. (2025) HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma. *Cancer research*, 85(4), 660.
- Bugide S, et al. (2024) ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models. *iScience*, 27(5), 109800.
- Chen N, et al. (2023) Biocompatibility of the oxygen carrier polymerized human hemoglobin towards HepG2/C3A cells. *Heliyon*, 9(5), e15878.
- N H, et al. (2023) In Vitro Hepatic Models to Assess Herb-Drug Interactions: Approaches and Challenges. *Pharmaceuticals (Basel, Switzerland)*, 16(3).
- Primadharsini PP, et al. (2023) Development and Characterization of Efficient Cell Culture Systems for Genotype 1 Hepatitis E Virus and Its Infectious cDNA Clone. *Viruses*, 15(4).
- Nyambo K, et al. (2023) In-silico and in-vitro assessments of some fabaceae, rhamnaceae, apocynaceae, and anacardiaceae species against *Mycobacterium tuberculosis* H37Rv and triple-negative breast cancer cells. *BMC complementary medicine and therapies*, 23(1), 219.
- Subramanian C, et al. (2023) Relief of CoA sequestration and restoration of mitochondrial function in a mouse model of propionic acidemia. *Journal of inherited metabolic disease*, 46(1), 28.
- Schrader JA, et al. (2023) EGF receptor modulates HEV entry in human hepatocytes. *Hepatology (Baltimore, Md.)*, 77(6), 2104.
- Hsieh YY, et al. (2023) Repositioning VU-0365114 as a novel microtubule-destabilizing agent for treating cancer and overcoming drug resistance. *Molecular oncology*.
- Lin S, et al. (2023) Hepatitis E Virus: Isolation, Propagation, and Quantification. *Current protocols*, 3(1), e642.
- Meister TL, et al. (2022) A ribavirin-induced ORF2 single-nucleotide variant produces defective hepatitis E virus particles with immune decoy function. *Proceedings of the National Academy of Sciences of the United States of America*, 119(34), e2202653119.
- Frandsen HS, et al. (2022) Mapping Proteome and Lipidome Changes in Early-Onset Non-Alcoholic Fatty Liver Disease Using Hepatic 3D Spheroids. *Cells*, 11(20).
- Wang M, et al. (2022) Molecularly cleavable bioinks facilitate high-performance digital light processing-based bioprinting of functional volumetric soft tissues. *Nature communications*, 13(1), 3317.
- Gabuza KB, et al. (2022) In vitro and in vivo hepatotoxicity study of Afriplex??? GRT through an inflammatory response. *Toxicology reports*, 9, 1920.
- Hernandez A, et al. (2022) Dihydroxyacetone suppresses mTOR nutrient signaling and induces mitochondrial stress in liver cells. *PLoS one*, 17(12), e0278516.